NeuroSense PrimeC clears safety hurdle in Alzheimer’s proof-of-concept trial
NeuroSense Therapeutics (NASDAQ:NRSN) reported on Monday the successful completion of a safety analysis for its Phase 2 NST-AD-001 study, a critical step in the company's efforts to repurpose its lead ALS candidate, PrimeC, for the treatment of Alzheimer’s disease.




-640x358.jpg&w=1200&q=75)
-640x358.jpg&w=1200&q=75)



